Mepolizumab Nucala®
The official Q-MEP product record describes mepolizumab as an anti-IL-5 IgG1 kappa monoclonal antibody. The SHIKARI® Mepolizumab portfolio supports quantitative measurement of mepolizumab and qualitative detection of specific anti-mepolizumab antibodies in human serum or plasma.
Why Mepolizumab is relevant to biological-drug monitoring research
Mepolizumab has clinically important target biology, indication-specific dosing and measurable systemic exposure, making drug concentration and immunogenicity relevant research variables. Scientific source ↗ · EMA source ↗
Molecular Target & Structure
Mepolizumab is a humanised IgG1κ monoclonal antibody that binds interleukin-5 and prevents IL-5 from engaging its receptor on eosinophils. Source ↗
Approved Indications
EMA-authorised uses include severe eosinophilic asthma, severe chronic rhinosinusitis with nasal polyps, eosinophilic granulomatosis with polyangiitis and hypereosinophilic syndrome in defined patients. EMA source ↗
Pharmacokinetic Persistence
A robust universal trough target is not established; regulator data instead provide context on persistence after subcutaneous administration:
Regulatory exposure values are regimen- and population-specific and are not therapeutic targets. Values vary with dose, timing, formulation and study population. This page is for RUO product information and does not provide clinical guidance.
Two complementary research assays
Ligand-binding, sandwich-principle ELISA for the quantitative analysis of free mepolizumab in human serum and plasma.
Sandwich-principle ELISA for the qualitative detection of antibodies to mepolizumab in human serum and plasma, reported as a positive or negative result according to the assay-specific cut-off criteria.
Kit Specifications at a Glance
| Kit Name | Catalog Code | Type | Analyte | ELISA Format | Tests | Storage |
|---|---|---|---|---|---|---|
| SHIKARI® Q-MEP | MEP-FD-NUC | Drug-Level Kit | Free mepolizumab | ELISA | 96 | 2–8°C |
| SHIKARI® S-ATM | MEP-QLS-NUC | Qualitative ADA Kit | Antibodies to mepolizumab | ELISA | 96 | 2–8°C |
Q-MEP has a lowest detection limit (LOD) of 20 ng/mL and functional sensitivity (LOQ) of 30 ng/mL. Follow the link on each assay card for the current official product record on matriksbiotek.com.
Which kit fits your research question?
Choose the drug-concentration assay or the qualitative anti-drug-antibody assay according to the required analytical output.
Mepolizumab Literature and Product-Use Records
Ready to order, or need technical guidance?
Matrix Biotek can help identify the appropriate Mepolizumab assay and prepare regional quotation and delivery information. SHIKARI® products are developed and manufactured in Ankara and supported through our European headquarters in Barcelona.